rs523349
A SNP in the SRD5A2 gene on chromosome 2. Its most notable genotype is C;C.
- Gene
- SRD5A2
- Location
- Chr 231,580,636 (GRCh38)
- Highest magnitude
- 0.0Typical
- Tested on
- 23andMe, AncestryDNA
- Minor allele frequency
- 34%
Genotypes
As shown in 23andMe and AncestryDNA files.
- C;CMost notableNot ratedNo summary available.
- C;GBadincreased ovarian cancer risk
- G;GGoodcommon in clinvar
On SNPedia: (C;C), (C;G), (G;G). Magnitude rates how notable a genotype is from 0 to 10, not how risky it is.
Frequency
Share of each genotype in 4 HapMap populations.
- AverageC;C 48% C;G 40% G;G 11%
- European ancestry (Utah)C;C 65% C;G 32% G;G 3%
- Han Chinese (Beijing)C;C 31% C;G 42% G;G 27%
- Japanese (Tokyo)C;C 40% C;G 49% G;G 12%
- Yoruba (Nigeria)C;C 59% C;G 38% G;G 3%
Related
Conditions, medicines and genes
Notes
From SNPedia
Show notes, about 130 words
rs523349 is a SNP in the steroid-5-alpha-reductase SRD5A2 gene; it is also known as V89L. In a study of a total of 1,466 Caucasian cases of ovarian cancer, the rs523349(G) allele showed a significant trend of increasing risk of ovarian cancer per rare allele (p = 0.00002). showed no association with ovarian cancer risk 4,624 invasive epithelial ovarian cancer cases and 8,113 controls of white non-Hispanic origin ovarian cancer {{PMID Auto |PMID=19914946 |Title=Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review }} {{PMID Auto |PMID=20855474 |Title=Association of Steroid 5{alpha} Reductase Type II Variants and Serum Androstane-3{alpha},17{beta}-Diol Glucuronide Concentration in Chinese Elderly Men }}
Source and license
Adapted from rs523349 on SNPedia, using a snapshot taken October 16, 2026. SNPedia content is shared under CC BY-NC-SA 3.0 US, and this page is shared under the same license.
SNPedia is a community-edited wiki. Its entries can be incomplete, out of date or wrong, and nothing here is a diagnosis or medical advice. Magnitude is a community rating of how interesting a genotype is, not a risk score.